Form 4: Dyne Therapeutics Chief Commercial Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, sold 143 shares of common stock on March 13, 2025, to cover tax obligations related to vesting restricted stock units.
Summary
- On March 13, 2025, Johanna Friedl-Naderer, the Chief Commercial Officer of Dyne Therapeutics, sold 143 shares of the company's common stock.
- The sale was executed at a price of $12.12 per share.
- This transaction was conducted to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) granted on December 4, 2024.
- The sale was automated as part of a pre-existing agreement consistent with Rule 10b5-1(c).
- Following the transaction, Friedl-Naderer still beneficially owns 96,057 shares, including 93,838 unvested RSUs.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction (sale of shares for tax obligations) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and are generally viewed as routine.
Key Dates
| Date | Description |
|---|---|
| December 4, 2024 | Date of restricted stock unit (RSU) grant to Johanna Friedl-Naderer. |
| March 13, 2025 | Date of stock sale by Johanna Friedl-Naderer to cover tax obligations. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.